Clinical Performance and Quality Measures for Adults With Acute ST-Elevation Myocardial Infarction in China

Обзор

This study aims to investigate and evaluate clinical performance and quality measures for adults with acute ST-elevation myocardial infarction (STEMI) in China. Further more, the investigates like to develop quality improvement strategies and relevant tools focusing on treatment and clinical outcome in patients with STEMI. This is a annually survey , through consecutively recruiting all eligible inpatients and collecting relevant medical information, the performance of all participating hospitals. Further, quality improvement strategies including summary of clinical performance and quality measures, clinical pathways and team building will be organized for the purpose of quality improvement. All hospitals will consecutively recruit qualified patients in the same method adopted in baseline period. Then the reperfusion rates and other performance measures will be compared annually.

Подробное описание

Cardiovascular disease (CVD) is a major concern in public health globally, as well as in China, and remarkable variations of resources available and health system performance have been noted. Acute myocardial infarction is one of the leading causes of mortality and morbidity, both in rural and urban area.

This study aims to investigate and evaluate clinical performance and quality measures for adults with acute ST-elevation myocardial infarction (STEMI) in China. Further more, the investigates like to develop quality improvement strategies and relevant tools focusing on treatment and clinical outcome in patients with STEMI.

This is a annually survey , through consecutively recruiting all eligible inpatients and collecting relevant medical information, the performance of all participating hospitals. Demographic characteristics, clinical features, diagnostic tests, medications, procedures, and in-hospital outcomes of patients will be obtained and then, the treatment pattern and outcomes will be evaluated. Further, quality improvement strategies including summary of clinical performance and quality measures, clinical pathways and professional training will be organized for the purpose of quality improvement. All hospitals will consecutively recruit qualified patients in the same method adopted in baseline period. Then the reperfusion rates and other performance measures will be compared annually.

New knowledge will be generated about STEMI management in China, to improve STEMI patients prognosis in future.

Вмешательства

• Поведенческое Quality improvement strategies and tools
  Quality improvement strategies and tools

Первичные конечные точки

• Aspirin at arrival [Срок оценки: 24 hours after admission]
• Clopidogrel (or ticagrelor) at arrival [Срок оценки: 24 hours after admission]
• β-blockers at arrival [Срок оценки: 24 hours after admission]
• ECG at arrival [Срок оценки: 24 hours after admission]
• Reperfusion therapy rate [Срок оценки: 24 hours after admission]
• Time delay from failure of fibrinolysis to angiography(The time from start of fibrinolysis to evaluation of its efficacy is 60-90min) [Срок оценки: 10 days on average (during hospitalization)]
• Time delay from start of fibrinolysis to angiography(if fibrinolysis is successful) [Срок оценки: 10 days on average (during hospitalization)]
• Timeliness of thrombolytic therapy [Срок оценки: 24 hours after admission]
• Timeliness of primary PCI [Срок оценки: 24 hours after admission]
• Door-in-Door-Out Time [Срок оценки: 24 hours after admission]

Критерии участия

Критерии включения

• Patients with STEMI who arrive at the hospital within 48 hours from the symptoms onset.

Критерии исключения

• None

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения

Только случаи

Центры проведения

Китай · 1 центр

• Hongjian Wang — Пекин

Идентификаторы

NCT: NCT04088682 · NCCQI-CAD

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗